MTNB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Matinas BioPharma Holdings Inc (MTNB) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of trading signals, and no significant catalysts make it prudent to hold off on investing right now.
The MACD is slightly positive but contracting, RSI is neutral at 37.396, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 0.609, with support at 0.575 and resistance at 0.643.
NULL identified. No news or significant insider/hedge fund activity.
The company has shown poor financial performance in Q3 2025, with a significant drop in net income (-49.71% YoY) and EPS (-67.06% YoY). No recent news or influential trading activity to support a positive outlook.
In Q3 2025, revenue remained at 0 with no growth, net income dropped to -$2,150,000 (-49.71% YoY), and EPS fell to -0.28 (-67.06% YoY). Gross margin remained at 0 with no improvement.
No recent analyst ratings or price target changes available.
